BR112012016128A2 - agente terapêutico (y-39983) para disfunção endotelial da córnea - Google Patents

agente terapêutico (y-39983) para disfunção endotelial da córnea

Info

Publication number
BR112012016128A2
BR112012016128A2 BR112012016128A BR112012016128A BR112012016128A2 BR 112012016128 A2 BR112012016128 A2 BR 112012016128A2 BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A2 BR112012016128 A2 BR 112012016128A2
Authority
BR
Brazil
Prior art keywords
corneal endothelial
therapeutic agent
corneal
endothelial cells
compound
Prior art date
Application number
BR112012016128A
Other languages
English (en)
Other versions
BR112012016128A8 (pt
Inventor
Hiroaki Takahashi
Takeshi Tarui
Tetsuo Kida
Yuji Sakamoto
Original Assignee
Mitsubishi Tanabe Pharma Corp
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Senju Pharma Co filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BR112012016128A2 publication Critical patent/BR112012016128A2/pt
Publication of BR112012016128A8 publication Critical patent/BR112012016128A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

agente terapêutico (y-39983) para disfunção endotelial da córnea. a presente invenção tem como objetivo um meio para o tratamento eficaz e conveniente de doenças onde células endoteliais da córnea pobres em t ermos de capacidade proliferativa in vivo são lesionadas. a presente invenção oferece um agente terapêutico para disfunção endotelial da córnea contendo (r)-(+)-n-(1h-pirrol[2,3-b]piridin-4-il)-4-(1-aminoetil)benzamida ou um sal farmacologicamente aceitável da mesma (composto (la)) como princípio ativo, um agente para promover adesão de células endoteliais da córnea, contendo o composto (la), um meio de cultura para células endoteliais da córnea, contendo o agente para promover adesão, um implante para ceratoplastia endotelial da córnea, containing células endoteliais da córnea, substrato e o composto (la), e um método de produção de uma preparação de endotélio corneano, incluindo uma etapa de cultivar células endoteliais da córnea usando o meio de cultura.
BR112012016128A 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea BR112012016128A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (2)

Publication Number Publication Date
BR112012016128A2 true BR112012016128A2 (pt) 2016-05-31
BR112012016128A8 BR112012016128A8 (pt) 2017-12-05

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016128A BR112012016128A8 (pt) 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea

Country Status (10)

Country Link
US (1) US20120288482A1 (pt)
EP (1) EP2519237A1 (pt)
JP (2) JP5750444B2 (pt)
KR (1) KR20120099147A (pt)
CN (1) CN102770136A (pt)
BR (1) BR112012016128A8 (pt)
CA (1) CA2785851A1 (pt)
MX (1) MX2012007671A (pt)
RU (1) RU2563141C2 (pt)
WO (2) WO2011080984A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041929T2 (hu) * 2011-12-06 2019-06-28 Astellas Inst For Regenerative Medicine Eljárás szaruhártya endotél sejtek irányított differenciálására
CA2931280A1 (en) 2013-11-27 2015-06-04 Senju Pharmaceutical Co., Ltd. Application of laminin to corneal endothelial cell culture
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
EP3199155B1 (en) * 2014-09-24 2021-06-16 Kowa Company, Ltd. Corneal thickness modulating agent
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
EP3213762B1 (en) 2014-10-31 2023-11-29 Kyoto Prefectural Public University Corporation Novel treatment of cornea using laminin
JP7008337B2 (ja) * 2016-02-15 2022-02-10 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
EP1378247B1 (en) 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1752456B1 (en) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
WO2006057270A1 (ja) * 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
US20090062295A1 (en) * 2005-03-10 2009-03-05 Mitsubishi Pharma Corporation Pharmaceutical Products
JP5255846B2 (ja) * 2006-01-19 2013-08-07 千寿製薬株式会社 生体内で細胞増殖可能な角膜内皮製剤
CN101495117B (zh) * 2006-07-31 2012-08-15 千寿制药株式会社 含酰胺化合物的水性液体制剂
CA2697895C (en) 2007-08-29 2017-10-31 Senju Pharmaceutical Co., Ltd. Agent for promoting corneal endothelial cell adhesion
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
JP5750444B2 (ja) 2015-07-22
US20120288482A1 (en) 2012-11-15
EP2519237A1 (en) 2012-11-07
CN102770136A (zh) 2012-11-07
JP2015155460A (ja) 2015-08-27
WO2011080984A1 (en) 2011-07-07
BR112012016128A8 (pt) 2017-12-05
CA2785851A1 (en) 2011-07-07
WO2011081221A1 (en) 2011-07-07
RU2012132443A (ru) 2014-02-10
JP2013515676A (ja) 2013-05-09
MX2012007671A (es) 2012-08-23
RU2563141C2 (ru) 2015-09-20
KR20120099147A (ko) 2012-09-06

Similar Documents

Publication Publication Date Title
BR112012016128A2 (pt) agente terapêutico (y-39983) para disfunção endotelial da córnea
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
BRPI0608152A2 (pt) formulações para tratamento ocular
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
WO2011034627A3 (en) Methods and apparatus for introducing cells at a tissue site
WO2011026614A3 (en) Compositions and methods for disinfecting materials
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
WO2008054544A3 (en) Method for delivery across the blood brain barrier
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2007119213A3 (en) A culture medium and pharmaceutical composition for regenerating cartilage tissue, a method, uses and products related thereto
UA84726C2 (ru) Производные простагландинов, способ их получения, фармацевтическая композиция (варианты) и способ лечения глаукомы или гипертензии глаза
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
BR112013012697A2 (pt) "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada."
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
MX2007012116A (es) Derivados de heteroaril urea utiles para inhibir chk1.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SENJU PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.